Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | +2.68% | -2.13% | +76.92% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 2
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 22-01-09 |
John Caloz
DFI | Director of Finance/CFO | 72 | 07-09-30 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Felix Kratz
PRN | Corporate Officer/Principal | - | 14-03-16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 21-07-28 |
Cary Claiborne
BRD | Director/Board Member | 64 | 22-07-26 |
Joel Caldwell
BRD | Director/Board Member | 69 | 17-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 495,092 | 492,306 ( 99.44 %) | 0 | 99.44 % |
Company contact information
LadRx Corp.
11726 San Vicente Boulevard Suite 650
90049, Los Angeles
+310 826 5648
http://www.ladrxcorp.comSector
1st Jan change | Capi. | |
---|---|---|
+76.92% | 1.14M | |
+17.09% | 44.63B | |
+42.10% | 40.46B | |
-9.70% | 38.07B | |
+33.28% | 32.27B | |
-8.98% | 27.3B | |
+13.37% | 26.53B | |
+44.11% | 14.06B | |
+32.33% | 12.54B | |
-7.26% | 11.28B |
- Stock Market
- Equities
- LADX Stock
- Company LadRx Corporation